- In men with type 2 diabetes mellitus (T2DM), testosterone replacement treatment (TRT) significantly improves sexual desire (SxD) in a greater proportion of men than placebo after 6 wk while the corresponding improvement in erectile function (EF) occurs later at 30 wk.
Why this matters
- SxD change after 6 wk predicting EF change at 30 wk is possibly a useful clinical finding.
- Using baseline total testosterone (TT)/free testosterone (FT), 30-wk randomised controlled study stratified 199 participants with T2DM into Mild (TT 8.1–12 nmol/L or FT 0.18–0.25 nmol/L) and Severe HG groups (TT ≤8 nmol/L and FT ≤0.18 nmol/L) and placebo – and testosterone undecanoate (TU)-treated groups.
- Associations between TU, SxD, and EF were investigated.
- Funding: None disclosed.
- Compared with placebo, a higher proportion of men in the severe HG group demonstrated improved SxD after 6 wk following TU treatment (Severe HG/P: 21.2%, Severe HG/TU: 60.0%, P<.001).
- Similarly, the proportion of men with improved EF after 30 wk was significantly higher in severe HG men.
- Logistic regression showed that SxD score at 6 wk (OR 3.31; P=.001) was significantly associated with the 30-wk EF score.
- Small sample size.